He-Wei granules (HWKL) combat cisplatin-induced nephrotoxicity. and myelosuppression in rats by inhibiting oxidative stress,

Transcript

1 Electronic Supplementary Material (ESI) for RSC Advances. This journal is The Royal Society of Chemistry 2017 He-Wei granules (HWKL) combat cisplatin-induced nephrotoxicity and myelosuppression in rats by inhibiting oxidative stress, inflammatory cytokines and apoptosis Zehai Song 1, Hang Chang 1, a Han 1, Hao Gao 1, Jingxuan Shao 1, Zhonglin Wang 1, Zhihui Liu 1, Ye Liu 2, Hui Wang 2, Jun Yin 1* 1 Development and Utilization Key Laboratory of ortheast Plant Materials, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang , China. 2 Beijing Handian Pharmaceutical Co., Ltd, Beijing , China. * Corresponding author Prof. Jun Yin School of Traditional Chinese Materia Medica 48 #, Shenyang Pharmaceutical University, Wenhua Road 103, Shenhe District, Shenyang , China TEL umb: FAX umb: yinjun2002@yahoo.com

2 Supplementary Fig. S1 The chemical structures of 37 constituents identified in the HWKL extract R 2 R 3 R 4 R 1 H Compound R 1 R 2 R 3 R 4 Scutellarin (7) H -glucuronyl H H Isomer of Chrysin-6-C- Arabinoside-8-C- C-arabinosyl H C-glucosyl H Glucoside (8) Chrysin-6-C- Arabinoside-8-C- C-glucosyl H C-arabinosyl H Glucoside (9) Baicalin (16) H -glucuronyl H H Isomer of baicalin (17) H -glucuronyl H H Wogonoside (21) H -glucuronyl CH3 H roxylin A 7-glucuronide (22) CH3 -glucuronyl H H Wogonin (36) H H CH3 H H H H C H H H H CH 3 HH acteoside (10)

3 R 2 R 1 Compound R 1 R 2 Liquiritigenin 7--Glucoside- 4 --Apiosyl--glucoside (3) -glucosyl -Apiosyl--glucosyl Liquiritin (4) H -glucosyl glu H H isoliquiritin (5) R 3 C R 2 R 4 CH H R 1 H H HC H H Compound R 1 R 2 R 3 R 4 22-β-Acetoxyl licorice saponin G2 (23) H H C CH 3 22-β- Acetoxylglycyrrhizic acid (24) H H C CH 3 Licorice saponin G2 (31) H H H

4 Licorice saponin J2 (33) H 2H H H CH CH H H H H H HC H Licorice saponin K2 (34) HC H CH H H HC H H Licorice saponin H2 (32) H 3 C H H CH 3 CH 3 H 3 C magnoflorine (2)

5 CH 3 H berberrubine (6) CH 3 CH 3 coptisine (11) epiberberine (12) H CH 3 H 3 C H 3 C columbamine (13) H H 3 C CH 3 CH 3 jatrorrhizine (14) H 3 C H 3 C CH 3 CH 3 palmatine (15)

6 CH 3 CH 3 berberine (18) R 3 H H R 1 R 2 Compound R 1 R 2 R 3 ginsenoside Rg1 (19) H -Glu Glu ginsenoside Re (20) H -Glu (2 1) Rha Glu 20SginsenosideRg2/20RginsenosideRg2 H -Glu (2 1) Rha H (25) ginsenoside Rb1 (26) Glu (1 2) Glu H Glu (6 1) Glu ginsenoside Rc (28) Glu (1 2) Glu H Glu (6 1) Ara (fu) ginsenoside Rb2 (29) Glu (1 2) Glu H Glu (6 1) Ara (py) ginsenoside Rb3 (30) Glu (1 2) Glu H Glu (6 1) Xyl ginsenoside Rd (35) Glu (1 2) Glu H Glu H CH 2 (CH 2 ) 3 CH 3 H CH 3 6-gingerol (37) H H H H H H H H sucrose (1) H H CH H pinellic acid (27)

7 Supplementary Table S1 The identified phytochemical compound and their properties and concentrations in HWKL extract detected by UHPLC-Q-TF-MS/MS o. Identification t R (min) Formula [M-H]- [M+HC]- [M+H]+ Fragment ions (MS 2 ) Source Contents (Mean ± SEM; mg/g) detected expected Error (ppm) detected expected Error (ppm) detected expected Error (ppm) 1 sucrose C12H * ± 11.0* 2 magnoflorine C20H , , , , CR 3 Liquiritigenin 7-- Glucoside-4 -- Apiosyl--glucoside C32H , , , GHR 4 Liquiritin C21H , , GHR ± Isoliquiritin C21H , GHR ± berberrubine C19H , , CR 7 Scutellarin C21H SR ± Isomer of Chrysin-6- C-Arabinoside-8-C- Glucoside C26H , , , SR 9 Chrysin-6-C- Arabinoside-8-C- Glucoside C26H , , , , SR 10 Acteoside C29H , , SR 11 coptisine C19H , , , CR 12 epiberberine C20H , CR

8 13 columbamine C20H jatrorrhizine C20H palmatine C21H baicalin C21H , , , , , , , , , , , , CR CR CR SR ± isomer of baicalin C21H , SR 18 berberine 7.87 C20H , , , , , CR 2.95 ± ginsenoside Rg C47H , , GR 0.90 ± ginsenoside Re C48H , GR 0.28 ± wogonoside C22H , SR roxylin A 7-glucuronide 22-β-Acetoxyl licorice saponin G C22H , SR C44H , GHR β- Acetoxylglycyrrhizic acid C44H , , , GHR 20S- 25 ginsenosiderg2/20r- ginsenosiderg C42H GR 26 ginsenoside Rb C54H , GR 0.72 ± 0.03

9 27 pinellic acid C18H PR 28 ginsenoside Rc C53H , , , GR 29 ginsenoside Rb C53H , GR 30 ginsenoside Rb C53H GR 31 Licorice saponin G C42H , , GHR 32 licorice saponin H C42H GHR 33 licorice saponin J C42H , GHR 34 licorice saponin K C42H GHR 35 ginsenoside Rd C48H , , GR 36 Wogonin C16H , SR 3.12 ± gingerol C17H , ZB 0.17 ± 0.05 PR:Pinelliae Rhizoma Praeparatum (Araceae), ZB:Zingiberis Rhizoma Recens (Zingiberaceae), GR:Ginseng Radix Et Rhizoma (Araliaceae), SR:Scutellariae Radix (Labiatae), CR:Coptidis Rhzima (Ranunculaceae), GHR:Glycyrrhizae Radix Et Rhizoma Praeparata Cum Melle (Leguminosae), JF:Jujubae Fructus (Rhamnaceae) *content of sucrose was measured as the total amount of polysaccharide * Polysaccharide are existed in all seven herbs so the source cannot be confirmed

10 Supplementary Table S2 Effect of HWKL on food consumptions at different time periods in cisplatin-treated rats ( ±SEM, g) blank cisplatin cisplatin + cisplatin + cisplatin + cisplatin + cisplatin + hwkl cisplatin + ondansetro domperido hwkl middle BXXXT low dose hwkl high dose n ne dose hwkl dose 7.0 mg/kg 1.3 mg/kg 3.0 mg/kg 1.38 g/kg 1.18 g/kg 2.36 g/kg g/kg 2.36 g/kg -72h ± ± ± ± ± ± ± ± ± h ± ± ± ± ± ± ± ± ± h ± ± ± ± ± ± ± ± ± h ± ± ± ± ± ± ± ± ± h ± ± 0.41 #### ± ± ± 0.53 ** ± 0.68 **** ± 1.53 **** ± 1.08 **** ± h ± ± 0.24 #### 7.99 ± ± ± ± 0.23 * ± 1.54 **** ± 1.94 **** ± h ± ± 0.01 #### 5.42 ± ± ± ± 0.95 **** ± 1.15 **** ± 3.07 **** ± h ± ± 0.56 #### 6.77 ± ± ± 1.04 * ± 1.43 **** ± 0.36 **** ± 0.45 **** ± h ± ± 0.32 #### 2.15 ± ± ± 0.78 ** ± 1.49 **** ± 1.89 **** ± 2.75 **** 34.09

11 ± h ± ± 0.76 #### ± ± ± 0.66 ** ± 1.28 *** ± 1.19 **** ± 0.93 **** ± h ± ± 0.75 #### ± ± ± 1.36 ** ± 1.35 **** ± 1.95 **** ± 1.29 **** ± 1.05 Values were represented as Mean±SEM. # p<0.05, ## p<0.01, ### p<0.001, #### p<0.0001, compared with the blank group, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, compared with the control group

12 Supplementary Table S3 Effect of HWKL on water consumptions at different time periods in cisplatin-treated rats ( ±SEM, g) cisplatin + cisplatin + cisplatin cisplatin + cisplatin + cisplatin + hwkl blank cisplatin hwkl low + hwkl ondansetron domperidone BXXXT middle dose high dose dose hwkl dose 7.0 mg/kg 1.3 mg/kg 3.0 mg/kg 1.38 g/kg 1.18 g/kg 2.36 g/kg g/kg 2.36 g/kg -72h ± ± ± ± ± h ± ± ± ± ± h ± ± ± ± ± h ± ± ± ± ± ± ± ± ± ± ± 24h ± ± 2.04 #### ± 1.84 ### ± 3.68 # 1.04 #### ± ± ± ± ± ± ± ± 48h ± ± 1.23 #### ± 1.98 #### ± 1.10 ## 0.82 #### 2.54 # ± ± ± ± 72h ± ± 1.08 #### ± 0.64 #### 0.93 #### 1.89 #### 1.77 # h ± ± 0.55 #### ± 5.03 ### ± 1.70 #### ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± 2.22

13 120h ± ± 2.21 #### ± 1.87 ### ± 2.15 #### ± ± ± ± ± h ± ± 2.45 ## ± 1.69 ### ± 0.50 #### ± ± ± ± ± h ± ± 1.29 ## ± ± ± ± ± ± ± 3.40 Values were represented as Mean±SEM. # p<0.05, ## p<0.01, ### p<0.001, #### p<0.0001, compared with the blank group

14 Supplementary Table S4 Effect of HWKL on body weight at different time periods in cisplatin-treated rats ( ±SEM, g) cisplatin + cisplatin + cisplatin + cisplatin + cisplatin + cisplatin + blank cisplatin ondansetro domperidon hwkl low hwkl hwkl high hwkl BXXXT n e dose middle dose dose dose 7.0 mg/kg 1.3 mg/kg 3.0 mg/kg 1.38 g/kg 1.18 g/kg 2.36 g/kg g/kg 2.36 g/kg -72h -48h -24h 0h 24h 48h 72h 96h 120h ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± 6.33 # 6.95 # 6.94 # ± ± ± ± 5.43 ### 7.45 ### 8.03 #### ± ± ± ± 5.53 #### 7.53 #### 9.11 #### ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± 3.11 *** ± ± ± ± 8.03 ** 5.41 **** ± ± 5.34 * ± ± ± ± ± ± ± ± ± 6.34 #### 9.46 #### 7.36 #### 7.07 # 8.34 # 7.51 * 8.20 *

15 144h 168h ± ± ± ± ± ± ± ± ± ± 6.55 #### 5.91 #### 7.42 #### 6.58 ## 7.28 # 8.27 ** 8.33 *** ± ± ± ± ± ± ± ± 9.26 #### 8.82 #### 6.28 #### 6.99 ## 6.66 # 4.34 **** 7.55 **** 8.96 Values were represented as Mean±SEM. # p<0.05, ## p<0.01, ### p<0.001, #### p<0.0001, compared with the blank group, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, compared with the control group, p<0.01, compared with the cisplatin + BXXXT group